Literature DB >> 7543247

Alterations in hepatic production and peripheral clearance of IGF-I after endotoxin.

J Fan1, D Char, A J Kolasa, W Pan, S R Maitra, C S Patlak, Z Spolarics, M C Gelato, C H Lang.   

Abstract

Lipopolysaccharide (LPS) produces a rapid and sustained reduction in the circulating concentration of insulin-like growth factor I (IGF-I), which may be responsible, in part, for the alterations in protein metabolism observed in these animals. The purpose of the present study was to determine whether this drop was due to a decreased hepatic production of IGF-I and/or an increased clearance of the peptide from the blood. Four hours after intravenous injection of LPS the plasma IGF-I concentration was decreased 50%. IGF-I release by in situ perfused livers from control rats was constant throughout the 60-min perfusion period and averaged 111 +/- 3 ng/min. In contrast, hepatic IGF-I output was decreased 46% by in vivo LPS. In contrast, livers from LPS-injected rats released more IGF binding proteins-1, -2 and -4 than did control livers. Hepatic cell isolation indicated that LPS decreased the IGF-I content in Kupffer and parenchymal cells, but not endothelial cells, by approximately 45%. Pharmacokinetic analysis of blood 125I-IGF-I decay curves indicated that the half-life for whole body clearance of 125I-IGF-I from the circulation was not altered by LPS. However, LPS increased 125I-IGF-I uptake by spleen, liver, lung, and kidney while decreasing uptake by the pancreas and gastrointestinal tract. These results indicate that the LPS-induced decrease in blood IGF-I concentration is primarily due to a reduction in hepatic production, not a change in whole body peptide clearance, and that a decreased production by both parenchymal and Kupffer cells contributes to this alteration.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7543247     DOI: 10.1152/ajpendo.1995.269.1.E33

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  7 in total

1.  Distinct mechanisms of induction of hepatic growth hormone resistance by endogenous IL-6, TNF-α, and IL-1β.

Authors:  Yueshui Zhao; Xiaoqiu Xiao; Stuart J Frank; Herbert Y Lin; Yin Xia
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-06-03       Impact factor: 4.310

2.  Suppression of insulin-like growth factor acid-labile subunit expression--a novel mechanism for deoxynivalenol-induced growth retardation.

Authors:  Chidozie J Amuzie; James J Pestka
Journal:  Toxicol Sci       Date:  2009-10-04       Impact factor: 4.849

Review 3.  Cytokine inhibition of JAK-STAT signaling: a new mechanism of growth hormone resistance.

Authors:  Charles H Lang; Ly Hong-Brown; Robert A Frost
Journal:  Pediatr Nephrol       Date:  2004-11-10       Impact factor: 3.714

4.  αMSH blunts endotoxin-induced MuRF1 and atrogin-1 upregulation in skeletal muscle by modulating NF-κB and Akt/FoxO1 pathway.

Authors:  Ana Isabel Martín; Ana Belén Gómez-SanMiguel; Carolina Gómez-Moreira; María Ángeles Villanúa; Asunción López-Calderón
Journal:  Mediators Inflamm       Date:  2014-09-09       Impact factor: 4.711

5.  Insulin-like growth factor 1 myocardial expression decreases in chronic alcohol consumption.

Authors:  Francesc Borrisser-Pairó; Emilia Antúnez; Ester Tobías; Joaquim Fernández-Solà
Journal:  Regen Med Res       Date:  2013-10-01

6.  D-TRP(8)-γMSH Prevents the Effects of Endotoxin in Rat Skeletal Muscle Cells through TNFα/NF-KB Signalling Pathway.

Authors:  Ana Belén Gómez-SanMiguel; María Ángeles Villanúa; Ana Isabel Martín; Asunción López-Calderón
Journal:  PLoS One       Date:  2016-05-13       Impact factor: 3.240

7.  The role of environmental enteric dysfunction in the pathogenesis of Schistosoma mansoni-associated morbidity in school-aged children.

Authors:  Jacqueline Araújo Fiuza; Susannah Colt; Letícia Gambogi de Ornellas; Leonardo Ferreira Matoso; Andrea Gazzinelli; Jennifer F Friedman; Rodrigo Corrêa-Oliveira
Journal:  PLoS Negl Trop Dis       Date:  2022-10-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.